Clinical Trials Browser

vandetanib × Head & Neck × Clear all

NCT01496313 2025-10-03

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Phase 4 Completed

81 enrolled 15 charts

Neoplasm Metastasis, Thyroid Neoplasms, Carcinoma, Medullary

NCT00410761 2025-09-24

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Phase 3 Completed

331 enrolled 15 charts

EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

Locally Advanced Thyroid Gland Carcinoma

NCT00537095 2024-04-19

Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

Phase 2 Completed

164 enrolled 10 charts

Thyroid Neoplasms

NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Phase 2 Terminated

6 enrolled 9 charts

EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT01414426 2021-01-14

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Phase 2 Completed

20 enrolled 7 charts

Head & NeckOther neoplasm

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Precancerous Conditions

NCT00923247 2018-11-29

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Phase 1/2 Terminated

22 enrolled 21 charts

Neoplasms, Thyroid Neoplasms, Carcinoma, Medullary

NCT00098345 2018-05-07

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

Phase 2 Completed

40 enrolled 12 charts

Thyroid Neoplasms

NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

BreastCNSEndocrineGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT00358956 2017-01-30

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Phase 2 Completed

19 enrolled 10 charts

EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

NCT00450138 2016-08-29

Open Label, Phase I ZD6474 Head and Neck Cancer Study

Phase 1 Completed

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00720083 2015-11-17

Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Phase 2 Terminated

34 enrolled 5 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00459043 2013-07-03

Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck

Phase 2 Completed

30 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck